MCID: PYL005
MIFTS: 56

Pyelonephritis

Categories: Nephrological diseases

Aliases & Classifications for Pyelonephritis

MalaCards integrated aliases for Pyelonephritis:

Name: Pyelonephritis 12 74 29 54 43 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:11400
ICD9CM 34 590.80
MeSH 43 D011704
NCIt 49 C34965
SNOMED-CT 67 45816000
ICD10 32 N16
UMLS 71 C0034186

Summaries for Pyelonephritis

MalaCards based summary : Pyelonephritis is related to chronic pyelonephritis and acute pyelonephritis. An important gene associated with Pyelonephritis is TLR4 (Toll Like Receptor 4), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Norfloxacin and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and prostate, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 74 Pyelonephritis is inflammation of the kidney, typically due to a bacterial infection. Symptoms most... more...

Related Diseases for Pyelonephritis

Diseases in the Pyelonephritis family:

Chronic Pyelonephritis Acute Pyelonephritis

Diseases related to Pyelonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1080)
# Related Disease Score Top Affiliating Genes
1 chronic pyelonephritis 33.8 UMOD TLR4 CRP CALCA ALB ACE
2 acute pyelonephritis 32.5 NAGLU LCN2 IL6 IL1A IL10 GPT
3 vesicoureteral reflux 1 31.8 UMOD NAGLU LCN2 CXCR1 CXCL8 CRP
4 glomerulonephritis 31.4 LCN2 IL1B CCL2 ALB ACE
5 pyuria 31.3 LCN2 IL6 GPT CXCL8 CRP ALB
6 pyelitis 31.3 UMOD TNF TLR4 LCN2 IL6 IL1B
7 hydronephrosis 31.3 NAGLU IL6 CXCL8 CRP CCL2 AMBP
8 cholecystitis 31.1 TLR4 GPT ALB
9 acute kidney failure 31.1 UMOD LCN2 GPT ALB
10 toxic shock syndrome 31.0 TNF TLR4 IL6 IL1B IL10 CXCL8
11 carbuncle 31.0 TNF IL6 IL1B
12 urolithiasis 31.0 UMOD IL6 IL1B AMBP ALB
13 fasciitis 31.0 TNF IL6 CXCL8 CRP
14 acute cystitis 31.0 UMOD TNF TLR4 LCN2 IL6 IL1B
15 nephrosclerosis 30.9 TNF CCL2 ACE
16 interstitial nephritis 30.9 UMOD CRP ALB ACE
17 amyloidosis 30.9 TNF IL6 IL1B CRP ALB
18 splenic abscess 30.9 GPT CRP ALB
19 nephrolithiasis 30.9 UMOD LCN2 IL1B AMBP ALB
20 prostatitis 30.9 TNF IL6 IL1B IL10 CXCL8
21 renal hypertension 30.9 CRP ALB ACE
22 infective endocarditis 30.8 TNF IL6 CRP
23 uremia 30.8 TNF IL6 CRP ALB ACE
24 necrotizing fasciitis 30.8 IL6 IL1B CXCL8 CRP ALB
25 disseminated intravascular coagulation 30.7 TNF IL6 IL10 GPT CRP
26 posterior urethral valves 30.7 TNF IL6 ACE
27 emphysematous cholecystitis 30.7 GPT CRP
28 diverticulitis 30.7 TNF IL6 CRP ALB
29 microvascular complications of diabetes 3 30.7 NAGLU ALB ACE
30 cystitis 30.7 UMOD TNF TLR4 IL6 IL1A CXCL8
31 bacteriuria 30.7 UMOD TLR4 IL6 CXCR2 CXCR1 CXCL8
32 spinal cord injury 30.7 TNF IL6 CXCL8
33 anuria 30.6 LCN2 GPT CRP ALB ACE
34 mycobacterium tuberculosis 1 30.6 TNF TLR4 IL10 CRP
35 deficiency anemia 30.5 TNF LCN2 IL6 CRP ALB ACE
36 endophthalmitis 30.5 TNF IL6 IL1B CXCL8 CRP ALB
37 nephrolithiasis, calcium oxalate 30.5 UMOD NAGLU AMBP
38 autosomal dominant polycystic kidney disease 30.5 TNF LCN2 CCL2 ALB ACE
39 urinary tract obstruction 30.5 UMOD TNF NAGLU LCN2 CRP CCL2
40 haemophilus influenzae 30.5 TNF CXCL8
41 thrombophlebitis 30.5 TNF CRP ALB
42 end stage renal disease 30.5 UMOD TNF IL6 CRP ALB ACE
43 polyarteritis nodosa 30.5 IL6 GPT CRP
44 lung abscess 30.5 TNF IL6 IL1B CRP ALB
45 urethritis 30.4 TNF TLR4 IL6 IL1B CXCL8 CRP
46 endocarditis 30.4 TNF IL6 IL1A IL10 CXCL8 CRP
47 epidemic typhus 30.4 TLR4 IL10 GPT CRP
48 aortic aneurysm, familial abdominal, 1 30.4 IL6 CRP CCL2 ACE
49 eclampsia 30.4 TNF IL6 ALB ACE
50 obstructive nephropathy 30.4 LCN2 CCL2 AMBP ALB ACE

Comorbidity relations with Pyelonephritis via Phenotypic Disease Network (PDN): (show all 20)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Cystitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hydronephrosis
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Kidney Disease
Nephrolithiasis, X-Linked Recessive, with Renal Failure Osteoporosis
Paralytic Ileus Protein-Energy Malnutrition
Schizophreniform Disorder Ureterolithiasis

Graphical network of the top 20 diseases related to Pyelonephritis:



Diseases related to Pyelonephritis

Symptoms & Phenotypes for Pyelonephritis

GenomeRNAi Phenotypes related to Pyelonephritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.5 CXCL8 IL10 IL1A IL1B LCN2 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.5 ACE CXCL8 IL10 IL1B LCN2 TNF
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.5 UMOD

MGI Mouse Phenotypes related to Pyelonephritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.28 ACE ALB CRP CXCL2 CXCR2 IL10
2 homeostasis/metabolism MP:0005376 10.18 ACE ALB CRP CXCR1 CXCR2 IL10
3 immune system MP:0005387 10.17 ACE ALB CCL2 CRP CXCR2 IL10
4 hematopoietic system MP:0005397 10.14 ACE CXCR1 CXCR2 IL10 IL1A IL1B
5 liver/biliary system MP:0005370 9.91 ACE ALB CXCR2 IL10 IL6 LCN2
6 neoplasm MP:0002006 9.81 ACE ALB CXCR2 IL10 IL1A IL1B
7 renal/urinary system MP:0005367 9.56 ACE ALB CXCR2 IL6 LCN2 NAGLU
8 skeleton MP:0005390 9.32 CXCL2 CXCR2 GPT IL10 IL1B IL6

Drugs & Therapeutics for Pyelonephritis

Drugs for Pyelonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norfloxacin Approved Phase 4 70458-96-7 4539
2
leucovorin Approved Phase 4 58-05-9 6006 143
3
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
4
Sulfamethoxazole Approved Phase 4 723-46-6 5329
5
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
6
Fosfomycin Approved Phase 4 23155-02-4 446987
7
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
8
Methenamine Approved, Vet_approved Phase 4 100-97-0 4101
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
11
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
12
Ofloxacin Approved Phase 4 82419-36-1 4583
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Antitubercular Agents Phase 4
16 Folic Acid Antagonists Phase 4
17 Vitamin B Complex Phase 4
18 Antiprotozoal Agents Phase 4
19 Antiparasitic Agents Phase 4
20 Folate Phase 4
21 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
22 Vitamin B9 Phase 4
23 Antimalarials Phase 4
24 Amdinocillin Pivoxil Phase 4
25 Lactams Phase 4
26 Methenamine mandelate Phase 4
27 Methenamine hippurate Phase 4
28 Pharmaceutical Solutions Phase 4
29 Analgesics, Non-Narcotic Phase 4
30 Analgesics Phase 4
31 Antipyretics Phase 4
32 Cyclooxygenase Inhibitors Phase 4
33 Antirheumatic Agents Phase 4
34 Anti-Inflammatory Agents Phase 4
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4
36
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
37
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
38
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
39
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
40
Racepinephrine Approved Phase 3 329-65-7 838
41 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
42
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
43
Ertapenem Approved, Investigational Phase 3 153832-46-3 150610
44
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
45
Sulbactam Approved Phase 3 68373-14-8
46
Vaborbactam Approved, Investigational Phase 3 1360457-46-0
47
Piperacillin Approved Phase 3 66258-76-2 43672
48
Colistin Approved Phase 3 1264-72-8, 1066-17-7 5311054
49
Tigecycline Approved Phase 3 220620-09-7 5282044
50
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682

Interventional clinical trials:

(show top 50) (show all 130)
# Name Status NCT ID Phase Drugs
1 Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis Unknown status NCT03179384 Phase 4 Ceftriaxone
2 Noroxin Efficacy and Safety Trial Unknown status NCT03506256 Phase 4 Norfloxacin 400 MG
3 Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old. Cefixime PO 10d vs Ceftriaxone IV 4d Followed by Cefixime PO 6d. Multicenter, Randomised Trial of Equivalence. Completed NCT00136656 Phase 4 antibiotic;antibiotics
4 Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux. Completed NCT00382343 Phase 4 Sulfamethoxazole/trimethoprim
5 Efficacy and Safety Study of Short Term Antibiotic During Seven Days With Ceftriaxone Intravenous the First Day Then Cefixime the Second Day Till the Seventh Day of Acute Uncomplicated Pyelonephritis in Women Between 18 and 65 Years Old Completed NCT01390623 Phase 4 Ceftriaxone
6 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward Completed NCT02246361 Phase 4
7 Pharmacokinetics of Ciprofloxacin in Pediatric Patients With Emphasis on Renal Excretion Completed NCT02598362 Phase 4 ciprofloxacin
8 The Efficacy and Safety of Pivmecillinam in Treating Bacteriemic Urosepsis Caused by E.Coli Completed NCT03282006 Phase 4 pivmecillinam
9 Randomized Controled Multicentric Trial, of Non Inferiority, Comparing Two Durations of Antibiotherapy (5 Days Versus 10 Days) in COMMUNAUTARY Acute Uncomplicated Pyelonephritis. Completed NCT00873626 Phase 4 levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)
10 Relevance of Biomarkers and Clinical Predictors of Outcome in Unselected Population With Febrile Urinary Tract Infection at Primary Care and Emergency Department in a Prospective, Randomized Cohort Trial Comparing Short (7 Days) Antibiotic Treatment With Conventional Treatment (14 Days) Completed NCT00809913 Phase 4 short treatment (ciprofloxacin)
11 Management of Sub-Clinical Bacteriuria in Pregnancy: A Feasibility Trial Completed NCT03275623 Phase 4 Antibiotic
12 Prospective, Open-Label, Noncomparative, Multicenter Study to Evaluate the Efficacy and Safety of Ciprofloxacin Extended Release (Cipro XR) 1000 mg Tablets Given Once Daily for 7 to 14 Days in the Treatment of Patients 18 Years or Older With Complicated Urinary Tract Infections Caused by Pseudomonas Aeruginosa and Other Common Uropathogens Completed NCT00481689 Phase 4 Cipro XR (Ciprofloxacin, BAYQ3939)
13 A Double-blind, Randomized, Placebo-controlled Phase IV Clinical Study of the Efficacy and Safety of a New Formulation of Paracetamol for the Management of Fever of Infectious Origin Completed NCT02283203 Phase 4 APOTEL max;Placebo
14 Perioperative Disodium Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients. Controlled Clinical Trial (PERIFOS Trial) Completed NCT03235947 Phase 4 Fosfomycin disodium;Trimethoprim / Sulfamethoxazole;Intravenous placebo
15 The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing Due to New Episodes of Urinary Tract Infections (UTI) in Elderly Women With Recurrent UTI - a Triple- Blinded, Randomized Placebo-controlled Phase IV Study Enrolling by invitation NCT04077580 Phase 4 Methenamine Hippurate 1000 MG
16 Comparing the Efficacy of Intravenous Paracetamol and Ketoprofen When Treating Renal Colic in Emergency Situations: a Randomized, Bi-centric, Double-blind Controlled Trial Suspended NCT01685658 Phase 4 Intravenous ketoprofen;Intravenous paracetamol
17 TREATMENT OF ACUTE UNCOMPLICATED PYELONEPHRITIS WITH SHORT COURSE LEVOFLOXACIN A Pilot Study Terminated NCT00239161 Phase 4 Levofloxacin
18 Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL) Producing and AmpC Hyperproducing Enterobacteriaceae in United Kingdom Withdrawn NCT01543347 Phase 4 Temocillin
19 The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
20 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
21 To Study the Effect of Adjunctive Oral Methylprednisolone Therapy in Pediatric Urinary Tract Infection Unknown status NCT02331862 Phase 3 Methylprednisolone
22 A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) in Japanese Patients With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection Completed NCT02728089 Phase 3 MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
23 A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Completed NCT03788967 Phase 3 Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr);Ertapenem
24 A Multicenter, Phase 3 Study of the Safety and Effectiveness of Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis Completed NCT00210990 Phase 3 doripenem
25 A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Verus a Comparator Antibiotic in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis Completed NCT00229021 Phase 3 doripenum
26 A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults Completed NCT01599806 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
27 A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults Completed NCT01595438 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
28 A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults Completed NCT02486627 Phase 3 plazomicin;meropenem;levofloxacin (oral)
29 A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis. Completed NCT00210886 Phase 3 levofloxacin
30 A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis Completed NCT01345929 Phase 3 CXA-201;Levofloxacin
31 Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis Completed NCT02166476 Phase 3 Meropenem-Vaborbactam;Piperacillin-Tazobactam;Levofloxacin;Saline
32 A Prospective, Multicenter, Noncomparative, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections Completed NCT00379951 Phase 3 ertapenem sodium
33 A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT01970371 Phase 3 plazomicin;colistin;meropenem;tigecycline;antibiotic of Investigator's choice
34 A Noncomparative, Multicenter, Open-Label, Study to Evaluate the Safety, Tolerability and Efficacy of MK0991 as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia Completed NCT00379964 Phase 3 caspofungin acetate
35 A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis. Completed NCT03687255 Phase 3 cefepime/AAI101 combination;Piperacillin/tazobactam
36 Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults Completed NCT02753946 Phase 2, Phase 3 ZTI-01;Piperacillin-tazobactam
37 A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections Completed NCT03032510 Phase 3 Eravacycline;Ertapenem;Placebo;Levofloxacin
38 A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT02168946 Phase 3 Vabomere;Best Available Therapy
39 Randomized, Double-blind, Double-dummy, Active-controlled, Multi-centre Trial to Compare the Efficacy and Safety of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) With Meropenem in Infections Caused by β-Lactamase (ESBL and MBL) Producing Gram-Negative Bacteria Completed NCT03477422 Phase 3 CSE-1034 (Ceftriaxone + Sulbactam + EDTA);Meropenem
40 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
41 A Double-blind Randomized Placebo-controlled Clinical Trial of the Safety and Efficacy of Intravenous Clarithromycin as Immunomodulatory Therapy for the Management of Sepsis Completed NCT01223690 Phase 3 Clarithromycin;Dextrose 5%
42 A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis Recruiting NCT03840148 Phase 3 Cefepime/VNRX-5133 (taniborbactam);Meropenem
43 Evaluation of the Efficiency of Autologous Adipocytes Graft in Endoscopic Treatment in Vesico-Renal Reflux in Children Recruiting NCT00367159 Phase 3
44 A Double-Blind, Randomized, Placebo-Controlled Clinical Study of the Efficacy of Intravenous Clarithromycin as Adjunctive Treatment in Patients With Sepsis and Respiratory and Multiple Organ Dysfunction Syndrome Active, not recruiting NCT03345992 Phase 3 Clarithromycin;Water for injection
45 A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem Followed by Optional Oral Therapy in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults Not yet recruiting NCT03630081 Phase 3 FEP-TAZ 4 g;Meropenem;ciprofloxacin 500 mg Optional Oral Switch
46 Randomised Controlled Trial on Efficacy and Safety of Short Term Versus Long Term Antibiotic Therapy for Pyelonephritis in Childhood. Terminated NCT00724256 Phase 3 ceftibuten;ceftibuten
47 A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infections Terminated NCT01110408 Phase 3 Doripenem;Doripenem placebo;Cefepime;Cefepime placebo;Amoxicillin/clavulanate potassium
48 A Phase 3, Randomized, Double-blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous Infusions of Flomoxef Versus Intravenous Infusions of Cefepime in the Treatment of Subjects With Complicated Urinary Tract Infections Including Pyelonephritis Terminated NCT02302092 Phase 3 Flomoxef;Cefepime
49 A Multicenter Randomized Controlled Trial of Antibiotic Treatment in Children With Urinary Tract Infections: Oral Amoxicillin/Clavulanic Acid Vs Initial Iv Ceftriaxone. Terminated NCT00161330 Phase 3 oral amoxicilline/clavulanic acid;iv ceftriaxone
50 A Randomized Controlled Trial of Antibiotic Prophylaxis in Children With Pyelonephritis in the Abscence of Vesicoureteral Reflux Withdrawn NCT00752375 Phase 3 Trimethoprim Sulfamethoxazole;placebo

Search NIH Clinical Center for Pyelonephritis

Cochrane evidence based reviews: pyelonephritis

Genetic Tests for Pyelonephritis

Genetic tests related to Pyelonephritis:

# Genetic test Affiliating Genes
1 Pyelonephritis 29

Anatomical Context for Pyelonephritis

MalaCards organs/tissues related to Pyelonephritis:

40
Kidney, Testes, Prostate, Colon, Neutrophil, Liver, Spinal Cord

Publications for Pyelonephritis

Articles related to Pyelonephritis:

(show top 50) (show all 12630)
# Title Authors PMID Year
1
Urinary N-acetyl-beta-D-glucosaminidase as a diagnostic marker of acute pyelonephritis in children. 54 61
19367005 2008
2
Doripenem: a review of its use in the treatment of bacterial infections. 61 54
18778123 2008
3
The multiple functions of Tamm-Horsfall protein in human health and disease: a mystery clears up. 54 61
15989109 2005
4
Tamm-Horsfall protein: a multilayered defence molecule against urinary tract infection. 61 54
15816991 2005
5
In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. 54 61
11801667 2002
6
Induction of innate immune responses by Escherichia coli and purified lipopolysaccharide correlate with organ- and cell-specific expression of Toll-like receptors within the human urinary tract. 61 54
11260138 2001
7
[Microproteinuria and enzymuria in fever and pyelonephritis in childhood. A prospective study of 180 children]. 61 54
9123685 1997
8
[Evaluation of N-acetyl-beta glucosaminidase in upper and lower urinary tract infections in childhood. Clinical study of 168 children]. 61 54
9064498 1996
9
dra-related X adhesins of gestational pyelonephritis-associated Escherichia coli recognize SCR-3 and SCR-4 domains of recombinant decay-accelerating factor. 61 54
7537246 1995
10
Urinary N-acetyl-beta-glucosaminidase and beta-2-microglobulin in the diagnosis of urinary tract infection in febrile infants. 61 54
8036046 1994
11
Urinary N-acetyl-beta-glucosaminidase in normal Chinese children and children with pyelonephritis. 61 54
2063674 1991
12
Urinary N-acetyl-beta-glucosaminidase and the selection of children for radiologic evaluation after urinary tract infection. 61 54
2371096 1990
13
A rare case of double kidney stones and Emphysematous Pyelonephritis presenting with septic shock. 61
32292702 2020
14
Kidney dendritic cells: fundamental biology and functional roles in health and disease. 61
32372062 2020
15
Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system. 61
32303061 2020
16
MDCT in the Setting of Suspected Colonic Diverticulitis: Prevalence and Diagnostic Yield for Diverticulitis and Alternative Diagnoses. 61
32319796 2020
17
Atypical focal xanthogranulomatous pyelonephritis without clinical symptoms presenting as infiltrative renal cancer: a case report and literature review. 61
32493295 2020
18
Xanthogranulomatous Ureteritis Mimicking Ureteral Involvement by Cancer in a Radical Cystectomy Specimen. 61
32493143 2020
19
A case of glomerulonephritis caused by brucellosis. 61
32508259 2020
20
Proprietary non-animal stabilized hyaluronic acid/dextranomer gel (NASHA/Dx) for endoscopic treatment of grade IV vesicoureteral reflux: Long-term observational study. 61
32414615 2020
21
Accuracy of subjective vesicoureteral reflux timing assessment: supporting new voiding cystourethrogram guidelines. 61
32185448 2020
22
Focal Xanthogranulomatous Pyelonephritis in Brachydactyly Mental Retardation Syndrome (2q37 Deletion Syndrome). 61
32341815 2020
23
Oral treatment of acute pyelonephritis: when, with which antimicrobial agent and for how long? 61
32536596 2020
24
Real-Time DMSA-SPECT/US Fusion Imaging Revealing Nonscarring Loss of Function After Pyelonephritis. 61
32332307 2020
25
Modeling the risk of fluoroquinolone resistance in non-severe community-onset pyelonephritis. 61
31997098 2020
26
Developmental loss, but not pharmacological suppression, of renal carbonic anhydrase 2 results in pyelonephritis susceptibility. 61
32390512 2020
27
High-salt diet aggravates pyelonephritis. 61
32286550 2020
28
Corticosteroids to prevent kidney scarring in children with a febrile urinary tract infection: a randomized trial. 61
32556960 2020
29
Is Non-Steroidal Anti-Inflammatory Therapy Non-Inferior to Antibiotic Therapy in Uncomplicated Urinary Tract Infections: a Systematic Review. 61
32270403 2020
30
Commentary to 'Diffusion weighted imaging is a promising method to detect acute pyelonephritis in non-sedated free breathing infants'. 61
32456875 2020
31
Diffusion weighted imaging is a promising method to detect acute pyelonephritis in non-sedated free breathing infants. 61
32336597 2020
32
Short vs long-course antibiotic therapy in pyelonephritis: a comparison of systematic reviews and guidelines for the SIMI choosing wisely campaign. 61
32566969 2020
33
Diabetes mellitus increases mortality in acute pyelonephritis patients: a population study based on the National Health Insurance Claim Data of South Korea for 2010-2014. 61
32301098 2020
34
Lack of Impact of Acute Pyelonephritis on Kidney Graft Survival. 61
32197868 2020
35
Relationship between low serum vitamin D status and urinary tract infection in children: a case-control study. 61
32490740 2020
36
Delayed Decompression of Obstructing Stones with Urinary Tract Infection is Associated with Increased Odds of Death. 61
32501124 2020
37
Evolving surgical management of pediatric vesicoureteral reflux: is open ureteral reimplantation still the 'Gold Standard'? 61
32167694 2020
38
Clinical Characteristics of Pediatric Pyelonephritis Without Pyuria or Bacteriuria. 61
32187138 2020
39
Urinary tract infections in children. 61
32446408 2020
40
A Case of Cytomegalovirus-Induced Hemophagocytic Lymphohistiocytosis in a Patient with an Underlying Rheumatic Disease. 61
32550050 2020
41
A computerized decision support system (CDSS) for antibiotic prescription in primary care-Antibioclic: implementation, adoption and sustainable use in the era of extended antimicrobial resistance. 61
32357226 2020
42
Scrub typhus as a rare cause of acute pyelonephritis: case report. 61
32375669 2020
43
Serum creatinine levels in cases of posterior urethral valve: 29 years experience of a pediatric urology reference center. 61
32424984 2020
44
Ureaplasma urealyticum infection presenting as pyelonephritis and perinephric abscess in an immunocompromised patient. 61
32414777 2020
45
Preventive Effect of L-Carnitine on Scar Formation During Acute Pyelonephritis: A Randomized Placebo-Controlled Trial. 61
30418227 2020
46
Emphysematous pyelonephritis caused by candida species: A case report and outcome of 1 year follow-up. 61
32055447 2020
47
Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis. 61
32451549 2020
48
Novel β-Lactam/β-Lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections: A meta-analysis of randomized controlled trials. 61
32384444 2020
49
Factors associated with preterm birth in women undergoing cervical cerclage. 61
32505054 2020
50
Emergence of Enteroaggregative Escherichia coli within the ST131 Lineage as a Cause of Extraintestinal Infections. 61
32430467 2020

Variations for Pyelonephritis

Expression for Pyelonephritis

Search GEO for disease gene expression data for Pyelonephritis.

Pathways for Pyelonephritis

Pathways related to Pyelonephritis according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TNF TLR4 LCN2 IL6 IL1B IL1A
2
Show member pathways
13.89 TNF IL6 IL1B IL1A IL10 CXCR2
3
Show member pathways
13.75 TNF TLR4 IL6 IL1B IL1A IL10
4
Show member pathways
13.47 TNF TLR4 IL6 IL1B IL1A IL10
5
Show member pathways
13.44 TNF LCN2 IL6 IL1B IL1A IL10
6
Show member pathways
13.37 TNF IL6 IL1B IL1A IL10 CXCR2
7
Show member pathways
13.14 TNF TLR4 IL6 IL1B IL10 CXCL8
8
Show member pathways
13.02 TNF TLR4 IL6 IL1B CXCR2 CXCL8
9
Show member pathways
12.93 TNF IL6 IL1B IL1A IL10 CXCL8
10
Show member pathways
12.91 TNF TLR4 IL6 IL1B IL1A CXCL8
11
Show member pathways
12.81 TNF TLR4 IL6 IL1B IL1A CXCL8
12
Show member pathways
12.76 TNF TLR4 IL6 IL1B IL1A
13
Show member pathways
12.7 TNF TLR4 IL6 IL1B IL1A IL10
14
Show member pathways
12.69 TNF TLR4 IL6 IL1B IL1A IL10
15
Show member pathways
12.66 TNF IL6 IL1B IL10 CCL2
16
Show member pathways
12.56 LCN2 CXCR2 CXCR1 CXCL8 CXCL2
17
Show member pathways
12.45 TNF LCN2 IL6 IL1B CXCL8 CXCL2
18
Show member pathways
12.44 TNF IL6 IL1B CRP CCL2 ALB
19 12.43 TNF TLR4 IL1B CXCL8
20
Show member pathways
12.43 TNF IL6 IL10 CXCR2 CXCR1 CXCL8
21
Show member pathways
12.42 TNF TLR4 IL6 IL1B IL1A CXCL8
22 12.41 TNF TLR4 IL6 IL1B CXCL8
23 12.37 TNF TLR4 IL6 IL1B CXCL8
24
Show member pathways
12.37 TNF TLR4 IL6 IL1A CXCL8
25
Show member pathways
12.36 TNF TLR4 IL1B IL1A IL10
26
Show member pathways
12.36 TNF IL6 IL1B IL1A IL10 CXCL8
27 12.35 TNF TLR4 IL6 IL1B CXCL8 CXCL2
28 12.34 TNF TLR4 IL6 IL1B IL1A IL10
29 12.29 TNF IL6 IL1B IL1A IL10 CXCL8
30
Show member pathways
12.28 TNF TLR4 IL6 IL1B CXCL8
31
Show member pathways
12.27 TNF IL6 IL1B IL10
32
Show member pathways
12.26 TNF TLR4 IL1B IL1A
33 12.17 TNF IL1B IL1A CCL2
34 12.13 TNF TLR4 IL6 IL1B IL10 CXCL8
35 12.09 TNF IL6 IL1B CXCL2 CCL2
36
Show member pathways
12.06 TNF TLR4 IL6 IL1B IL10
37 12.05 TNF TLR4 IL1B CXCL8 CXCL2
38 12.03 IL6 IL1B IL1A CXCL8
39 12.03 TNF IL6 IL1B IL1A CXCL8 CCL2
40 12.03 TNF TLR4 IL6 IL1B IL10 CXCL8
41 12 TNF IL6 IL1B IL1A
42 12 TNF TLR4 IL6 IL1B IL1A CXCL8
43 11.92 TNF LCN2 IL6 IL1B IL1A IL10
44 11.87 TNF IL6 IL1B IL10
45 11.86 TNF TLR4 IL6 IL1B IL1A IL10
46 11.82 TNF IL1B IL10
47
Show member pathways
11.81 TNF IL6 IL1B IL1A CXCL8 CXCL2
48 11.76 TNF TLR4 IL6 IL1B CXCL8 CXCL2
49 11.71 TNF IL6 IL1B CXCL8 CXCL2 CCL2
50 11.64 TNF TLR4 IL1A

GO Terms for Pyelonephritis

Cellular components related to Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 UMOD TNF LCN2 IL6 IL1B IL1A
2 external side of plasma membrane GO:0009897 9.55 TNF TLR4 CXCR2 CXCR1 ACE
3 extracellular space GO:0005615 9.53 UMOD TNF LCN2 IL6 IL1B IL1A

Biological processes related to Pyelonephritis according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.36 TLR4 IL6 IL1B IL10 CXCR2 CXCR1
2 negative regulation of cell proliferation GO:0008285 10.09 UMOD IL6 IL1B IL1A IL10 CXCL8
3 positive regulation of gene expression GO:0010628 10.04 TNF TLR4 LCN2 IL6 IL1B IL1A
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.01 TNF TLR4 IL1B IL1A
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 10 TNF TLR4 IL6 IL1B
6 positive regulation of angiogenesis GO:0045766 9.99 IL1B IL1A CXCR2 CXCL8
7 cellular response to tumor necrosis factor GO:0071356 9.98 LCN2 CXCL8 CCL2 CALCA
8 chemotaxis GO:0006935 9.96 CXCR2 CXCR1 CXCL8 CXCL2 CCL2
9 positive regulation of DNA-binding transcription factor activity GO:0051091 9.94 TNF IL6 IL1B IL10
10 cytokine-mediated signaling pathway GO:0019221 9.91 TNF LCN2 IL6 IL1B IL1A IL10
11 cellular response to organic cyclic compound GO:0071407 9.9 TNF IL1B CCL2
12 response to glucocorticoid GO:0051384 9.9 TNF IL6 IL10
13 immune response GO:0006955 9.9 TNF TLR4 IL6 IL1B IL1A IL10
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.89 TNF TLR4 IL1B
15 humoral immune response GO:0006959 9.89 TNF IL6 CCL2
16 cell chemotaxis GO:0060326 9.89 CXCR2 CXCR1 CXCL2 CCL2
17 positive regulation of interferon-gamma production GO:0032729 9.87 TNF TLR4 IL1B
18 monocyte chemotaxis GO:0002548 9.87 IL6 CCL2 CALCA
19 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 TNF TLR4 IL1B
20 protein kinase B signaling GO:0043491 9.85 TNF IL1B CCL2
21 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.85 TNF IL1B IL1A
22 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.84 LCN2 IL1B IL1A
23 negative regulation of interleukin-6 production GO:0032715 9.84 TNF TLR4 IL10
24 positive regulation of interleukin-6 production GO:0032755 9.84 TNF TLR4 IL6 IL1B
25 positive regulation of cytokine secretion GO:0050715 9.82 TNF IL1A IL10
26 positive regulation of JAK-STAT cascade GO:0046427 9.82 TNF IL6 IL10
27 positive regulation of vascular endothelial growth factor production GO:0010575 9.81 IL6 IL1B IL1A
28 negative regulation of neurogenesis GO:0050768 9.8 TNF IL6 IL1B
29 neutrophil chemotaxis GO:0030593 9.8 IL1B CXCR2 CXCR1 CXCL8 CXCL2 CCL2
30 leukocyte chemotaxis GO:0030595 9.78 IL10 CXCL8 CXCL2
31 receptor internalization GO:0031623 9.78 CXCR2 CXCR1 CXCL8 CALCA
32 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.77 TNF TLR4 IL6
33 chemokine-mediated signaling pathway GO:0070098 9.77 CXCR2 CXCR1 CXCL8 CXCL2 CCL2
34 positive regulation of chemokine production GO:0032722 9.76 TNF TLR4 IL6
35 positive regulation of interleukin-6 secretion GO:2000778 9.76 TNF TLR4 IL1B IL1A
36 positive regulation of glial cell proliferation GO:0060252 9.75 TNF IL6 IL1B
37 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 TNF IL1B IL10
38 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 TLR4 IL10
39 lipopolysaccharide-mediated signaling pathway GO:0031663 9.73 TNF TLR4 IL1B CCL2
40 regulation of establishment of endothelial barrier GO:1903140 9.72 TNF IL1B
41 endothelial cell apoptotic process GO:0072577 9.72 TNF IL10
42 neutrophil mediated immunity GO:0002446 9.72 IL6 ACE
43 positive regulation of neuroinflammatory response GO:0150078 9.72 TNF IL6 IL1B
44 ectopic germ cell programmed cell death GO:0035234 9.71 IL1B IL1A
45 negative regulation of cytokine production involved in immune response GO:0002719 9.71 TNF IL10
46 positive regulation of interleukin-8 production GO:0032757 9.71 TNF TLR4 IL1B CALCA
47 positive regulation of fever generation GO:0031622 9.7 TNF IL1B
48 negative regulation of cytokine secretion involved in immune response GO:0002740 9.7 TNF IL10
49 response to molecule of bacterial origin GO:0002237 9.7 IL10 CXCL8 CXCL2
50 inflammatory response GO:0006954 9.7 TNF TLR4 IL6 IL1B IL1A CXCR2

Molecular functions related to Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.5 CXCL8 CXCL2 CCL2
2 C-X-C chemokine receptor activity GO:0016494 9.37 CXCR2 CXCR1
3 interleukin-8 binding GO:0019959 9.26 CXCR2 CXCR1
4 cytokine activity GO:0005125 9.23 TNF IL6 IL1B IL1A IL10 CXCL8
5 enterobactin binding GO:1903981 9.16 LCN2 ALB
6 interleukin-8 receptor activity GO:0004918 8.96 CXCR2 CXCR1

Sources for Pyelonephritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....